With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.
234b) Ethyl 1 -(2,-fluoro-3′-((tetrahydro-2H-pyran-4-yl)oxy)-[1 ,1 ‘-biphenyl]-3-yl)-5-(2- (1 -methyl-1 H-1 ,2,3-triazol-4-yl)cyclopropyl)-1 H-pyrazole-4-carboxylate To a solution of ethyl 1 -(2′-fluoro-3’-hydroxy-[1 ,1 ‘-biphenyl]-3-yl)-5-(2-(1 -methyl-1 H-1 ,2,3- triazol-4-yl)cyclopropyl)-1 H-pyrazole-4-carboxylate (450 mg, 1 .006 mmol) in N,N- dimethylformamide (DMF) (5 mL) was added Cs2C03 (655 mg, 2.01 1 mmol) and 4- bromotetrahydro-2H-pyran (232 mg, 1 .408 mmol). It was heated in Microwave at 120 C for 2 h. The reaction mixture was diluted with water and extracted with ethyl acetate (2 x 30 mL). The combined organic layer was washed with chilled water (3 x 30 mL) and then brine solution (30 mL), dried over anhydrous Na2S04 and concentrated. The crude residue was purified by column chromatography eluting with 1 % methanol in DCM. Desired fractions were concentrated to give the title compound (200 mg, 0.217 mmol, 21 .58 % yield). LC-MS m/z 532.23 (M+H)+, 2.36 min (ret. time)., 25637-16-5
As the paragraph descriping shows that 25637-16-5 is playing an increasingly important role.
Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; ASTEX THERAPEUTICS LIMITED; CALLAHAN, James Francis; KERNS, Jeffrey K.; LI, Peng; LI, Tindy; MCCLELAND, Brent W.; NIE, Hong; PERO, Joseph E.; DAVIES, Thomas Glanmor; GRAZIA CARR, Maria; GRIFFITHS-JONES, Charlotte Mary; HEIGHTMAN, Thomas Daniel; NORTON, David; VERDONK, Marinus Leendert; WOOLFORD, Alison Jo-Anne; WILLEMS, Hendrika Maria Gerarda; (664 pag.)WO2017/60854; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics